Skip to main content

Table 1 Abscopal effect of AGI-134 in in four independent experiments: incidence of distal B16-F10 tumor development after treatment of a primary B16-F10 tumor with AGI-134 or vehicle

From: AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Experiment #

Observation period (days)

Mice with 2° tumors at end of the observation period

Mantel–Cox test results

AGI-134 group

PBS group

1

25

2/10 (20%)

8/10 (80%)

**p = 0.0017

2

31

2/10 (20%)

8/10 (80%)

*p = 0.009

3

32

0/7 (0%)

7/7 (100%)

***p = 0.0002

4

32

2/10 (20%)

10/10 (100%)

***p = 0.0004